Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Correction for Israeli et al., "Draft Genome Sequence of a Rare Israeli Clinical Isolate of Burkholderia pseudomallei".

Israeli O, Cohen-Gihon I, Brosh-Nissimov T, Weiss S, Zvi A, Beth-Din A, Shifman O, Israeli M, Elia U, Lazar S, Bar-Haim E, Cohen O, Chitlaru T.

Microbiol Resour Announc. 2019 Oct 3;8(40). pii: e01105-19. doi: 10.1128/MRA.01105-19. No abstract available.

2.

Early Diagnosis of Pathogen Infection by Cell-Based Activation Immunoassay.

Bar-Haim E, Rotem S, Elia U, Bercovich-Kinori A, Israeli M, Cohen-Gihon I, Israeli O, Erez N, Achdout H, Zauberman A, Aftalion M, Mamroud E, Chitlaru T, Cohen O.

Cells. 2019 Aug 22;8(9). pii: E952. doi: 10.3390/cells8090952.

3.

Case Report: Imported Melioidosis from Goa, India to Israel, 2018.

Brosh-Nissimov T, Grupel D, Abuhasira S, Leskes H, Israeli M, Lazar S, Elia U, Israeli O, Beth-Din A, Bar-Haim E, Cohen-Gihon I, Zvi A, Cohen O, Chitlaru T.

Am J Trop Med Hyg. 2019 Sep;101(3):580-584. doi: 10.4269/ajtmh.19-0303.

PMID:
31287043
4.

Disruption of the NlpD lipoprotein of the plague pathogen Yersinia pestis affects iron acquisition and the activity of the twin-arginine translocation system.

Tidhar A, Levy Y, Zauberman A, Vagima Y, Gur D, Aftalion M, Israeli O, Chitlaru T, Ariel N, Flashner Y, Zvi A, Mamroud E.

PLoS Negl Trop Dis. 2019 Jun 6;13(6):e0007449. doi: 10.1371/journal.pntd.0007449. eCollection 2019 Jun.

5.

Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.

Zauberman A, Gur D, Levy Y, Aftalion M, Vagima Y, Tidhar A, Chitlaru T, Mamroud E.

J Infect Dis. 2019 Aug 30;220(7):1147-1151. doi: 10.1093/infdis/jiz260.

PMID:
31095689
6.

Draft Genome Sequence of a Rare Israeli Clinical Isolate of Burkholderia pseudomallei.

Israeli O, Cohen-Gihon I, Brosh-Nissimov T, Zvi A, Beth-Din A, Shifman O, Israeli M, Elia U, Lazar S, Bar-Haim E, Cohen O, Chitlaru T.

Microbiol Resour Announc. 2019 May 9;8(19). pii: e00281-19. doi: 10.1128/MRA.00281-19. Erratum in: Microbiol Resour Announc. 2019 Oct 3;8(40):.

7.

Distinct Contribution of the HtrA Protease and PDZ Domains to Its Function in Stress Resilience and Virulence of Bacillus anthracis.

Israeli M, Elia U, Rotem S, Cohen H, Tidhar A, Bercovich-Kinori A, Cohen O, Chitlaru T.

Front Microbiol. 2019 Feb 18;10:255. doi: 10.3389/fmicb.2019.00255. eCollection 2019.

8.

Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague.

Levy Y, Vagima Y, Tidhar A, Aftalion M, Gur D, Nili U, Chitlaru T, Zauberman A, Mamroud E.

NPJ Vaccines. 2018 Oct 19;3:52. doi: 10.1038/s41541-018-0087-z. eCollection 2018.

9.

Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung.

Bar-On L, Cohen H, Elia U, Rotem S, Bercovich-Kinori A, Bar-Haim E, Chitlaru T, Cohen O.

Vaccine. 2017 Dec 15;35(50):7001-7009. doi: 10.1016/j.vaccine.2017.10.053. Epub 2017 Nov 6.

PMID:
29102170
10.

Host Iron Nutritional Immunity Induced by a Live Yersinia pestis Vaccine Strain Is Associated with Immediate Protection against Plague.

Zauberman A, Vagima Y, Tidhar A, Aftalion M, Gur D, Rotem S, Chitlaru T, Levy Y, Mamroud E.

Front Cell Infect Microbiol. 2017 Jun 21;7:277. doi: 10.3389/fcimb.2017.00277. eCollection 2017.

11.

A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.

Chitlaru T, Israeli M, Rotem S, Elia U, Bar-Haim E, Ehrlich S, Cohen O, Shafferman A.

Vaccine. 2017 Oct 20;35(44):6030-6040. doi: 10.1016/j.vaccine.2017.03.033. Epub 2017 Mar 23.

PMID:
28342664
12.

A Simple Luminescent Adenylate-Cyclase Functional Assay for Evaluation of Bacillus anthracis Edema Factor Activity.

Israeli M, Rotem S, Elia U, Bar-Haim E, Cohen O, Chitlaru T.

Toxins (Basel). 2016 Aug 18;8(8). pii: E243. doi: 10.3390/toxins8080243.

13.

Adjunctive Corticosteroid Treatment Against Yersinia pestis Improves Bacterial Clearance, Immunopathology, and Survival in the Mouse Model of Bubonic Plague.

Levy Y, Vagima Y, Tidhar A, Zauberman A, Aftalion M, Gur D, Fogel I, Chitlaru T, Flashner Y, Mamroud E.

J Infect Dis. 2016 Sep 15;214(6):970-7. doi: 10.1093/infdis/jiw290. Epub 2016 Jul 11.

PMID:
27402776
14.

Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.

Chitlaru T, Israeli M, Bar-Haim E, Elia U, Rotem S, Ehrlich S, Cohen O, Shafferman A.

Sci Rep. 2016 Jan 6;6:18908. doi: 10.1038/srep18908.

15.

Whole-Genome Sequencing of the Nonproteolytic Bacillus anthracis V770-NP1-R Strain Reveals Multiple Mutations in Peptidase Loci.

Cohen-Gihon I, Israeli O, Beth-Din A, Levy H, Cohen O, Shafferman A, Zvi A, Chitlaru T.

Genome Announc. 2014 Feb 13;2(1). pii: e00075-14. doi: 10.1128/genomeA.00075-14.

16.

HtrA is a major virulence determinant of Bacillus anthracis.

Chitlaru T, Zaide G, Ehrlich S, Inbar I, Cohen O, Shafferman A.

Mol Microbiol. 2011 Sep;81(6):1542-59. doi: 10.1111/j.1365-2958.2011.07790.x. Epub 2011 Aug 23.

17.

Progress and novel strategies in vaccine development and treatment of anthrax.

Chitlaru T, Altboum Z, Reuveny S, Shafferman A.

Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Review.

PMID:
21198675
18.

Proteomic studies of Bacillus anthracis.

Chitlaru T, Shafferman A.

Future Microbiol. 2009 Oct;4(8):983-98. doi: 10.2217/fmb.09.73. Review.

PMID:
19824790
19.

Novel and unique diagnostic biomarkers for Bacillus anthracis infection.

Sela-Abramovich S, Chitlaru T, Gat O, Grosfeld H, Cohen O, Shafferman A.

Appl Environ Microbiol. 2009 Oct;75(19):6157-67. doi: 10.1128/AEM.00766-09. Epub 2009 Jul 31.

20.

Characterization of Bacillus anthracis iron-regulated surface determinant (Isd) proteins containing NEAT domains.

Gat O, Zaide G, Inbar I, Grosfeld H, Chitlaru T, Levy H, Shafferman A.

Mol Microbiol. 2008 Nov;70(4):983-99. doi: 10.1111/j.1365-2958.2008.06460.x. Epub 2008 Sep 30.

21.

Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.

Chitlaru T, Gat O, Grosfeld H, Inbar I, Gozlan Y, Shafferman A.

Infect Immun. 2007 Jun;75(6):2841-52. Epub 2007 Mar 12.

22.

Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Gat O, Grosfeld H, Ariel N, Inbar I, Zaide G, Broder Y, Zvi A, Chitlaru T, Altboum Z, Stein D, Cohen S, Shafferman A.

Infect Immun. 2006 Jul;74(7):3987-4001.

24.

The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant.

Gat O, Mendelson I, Chitlaru T, Ariel N, Altboum Z, Levy H, Weiss S, Grosfeld H, Cohen S, Shafferman A.

Mol Microbiol. 2005 Oct;58(2):533-51.

25.
26.

Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens.

Ariel N, Zvi A, Makarova KS, Chitlaru T, Elhanany E, Velan B, Cohen S, Friedlander AM, Shafferman A.

Infect Immun. 2003 Aug;71(8):4563-79.

27.
28.

Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity.

Cohen O, Kronman C, Chitlaru T, Ordentlich A, Velan B, Shafferman A.

Biochem J. 2001 Aug 1;357(Pt 3):795-802.

29.

Effect of human acetylcholinesterase subunit assembly on its circulatory residence.

Chitlaru T, Kronman C, Velan B, Shafferman A.

Biochem J. 2001 Mar 15;354(Pt 3):613-25.

31.

Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels.

Chitlaru T, Kronman C, Zeevi M, Kam M, Harel A, Ordentlich A, Velan B, Shafferman A.

Biochem J. 1998 Dec 15;336 ( Pt 3):647-58.

Supplemental Content

Loading ...
Support Center